

Kangho Suh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6179399/publications.pdf>

Version: 2024-02-01

19
papers

336
citations

1162367

8
h-index

887659

17
g-index

19
all docs

19
docs citations

19
times ranked

626
citing authors

#	ARTICLE	IF	CITATIONS
1	Latent Class Analysis of Prescribing Behavior of Primary Care Physicians in the Veterans Health Administration. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	3
2	The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-9.	0.5	0
3	Consensus Obtained for the Nephrotoxic Potential of 167 Drugs in Adult Critically Ill Patients Using a Modified Delphi Method. <i>Drug Safety</i> , 2022, 45, 389-398.	1.4	20
4	Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 193-204.	1.0	1
5	Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients. <i>BioDrugs</i> , 2021, 35, 61-73.	2.2	1
6	Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. <i>Journal of Medical Economics</i> , 2021, 24, 563-569.	1.0	5
7	International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 670.	1.2	1
8	A systematic review of cost-effectiveness analyses across the acute kidney injury landscape. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 571-578.	0.7	3
9	Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 80.	1.0	2
10	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1033-1040.	1.5	13
11	Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease: Protocol and Baseline Results for a Comparative Effectiveness Study. <i>JMIR Research Protocols</i> , 2020, 9, e14936.	0.5	8
12	Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. <i>Value in Health</i> , 2019, 22, 648-655.	0.1	7
13	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2018, 36, 495-504.	1.7	24
14	Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 1084-1090.	0.5	7
15	Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 32-37.	0.5	17
16	Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel®. <i>Advances in Therapy</i> , 2016, 33, 1279-1292.	1.3	19
17	Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 37.	0.7	34
18	Health economics and outcomes research fellowship practices reviewed. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, 280-287.	1.5	2

#	ARTICLE	IF	CITATIONS
19	Economic Burden of COPD in the Presence of Comorbidities. Chest, 2015, 148, 138-150.	0.4	169